Target Price | $79.54 |
Price | $47.25 |
Potential |
68.34%
register free of charge
|
Number of Estimates | 24 |
24 Analysts have issued a price target CRISPR Therapeutics AG 2025 .
The average CRISPR Therapeutics AG target price is $79.54.
This is
68.34%
register free of charge
$199.00
321.16%
register free of charge
$30.00
36.51%
register free of charge
|
|
A rating was issued by 30 analysts: 15 Analysts recommend CRISPR Therapeutics AG to buy, 12 to hold and 3 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the CRISPR Therapeutics AG stock has an average upside potential 2025 of
68.34%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Million $ | 371.21 | 20.72 |
30,834.17% | 94.42% | |
EBITDA Margin | -54.61% | -2,466.67% |
99.90% | 4,417.28% | |
Net Margin | -44.60% | -2,037.20% |
99.92% | 4,467.71% |
27 Analysts have issued a sales forecast CRISPR Therapeutics AG 2024 . The average CRISPR Therapeutics AG sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an CRISPR Therapeutics AG EBITDA forecast 2024. The average CRISPR Therapeutics AG EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
8 CRISPR Therapeutics AG Analysts have issued a net profit forecast 2024. The average CRISPR Therapeutics AG net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | -1.94 | -4.95 |
76.79% | 155.15% | |
P/E | negative | |
EV/Sales | 112.19 |
8 Analysts have issued a CRISPR Therapeutics AG forecast for earnings per share. The average CRISPR Therapeutics AG <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the CRISPR Therapeutics AG stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
CRISPR Therapeutics AG...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.